New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
14:41 EDTJAZZJazz Pharmaceuticals says all endpoints met in JZP-110 Phase 2b study
Jazz Pharmaceuticals presented data from the Phase 2b study evaluating JZP-110 as a potential new treatment for the symptoms of excessive daytime sleepiness in adults with narcolepsy. In the study, all primary and secondary endpoints were met and patients treated with JZP-110 experienced statistically significant improvements in objective and subjective symptoms of EDS. Based on these data, Jazz Pharmaceuticals plans to evaluate JZP-110 in Phase 3 clinical studies in patients with EDS associated with narcolepsy and in patients with EDS associated with obstructive sleep apnea, pending discussions with regulatory agencies. These data were presented at a late-breaker session during SLEEP 2014, the 28th Annual Meeting of the Associated Professional Sleep Societies, in Minneapolis, Minn. The annual SLEEP meeting is the premier U.S. conference for healthcare professionals, advocates and industry partners involved in sleep medicine. "We are committed to developing and commercializing new and differentiated therapies that address unmet patient needs in sleep medicine, and we believe, based on the encouraging results from early clinical trials, that JZP-110 has the potential to significantly help people with narcolepsy and OSA who are experiencing EDS," said Jeffrey Tobias, M.D., executive vice president, research and development, and chief medical officer, Jazz Pharmaceuticals. "As one of the newest additions to our growing sleep clinical development pipeline, we look forward to advancing the Phase 3 clinical program for this product candidate."
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
09:46 EDTJAZZAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
August 19, 2014
13:28 EDTJAZZJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
10:13 EDTJAZZOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:20 EDTJAZZJazz Pharmaceuticals initiated with an Overweight at JPMorgan
Subscribe for More Information
August 18, 2014
11:41 EDTJAZZCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 15, 2014
08:11 EDTJAZZJazz Pharmaceuticals management meeting strengthens postive view, says Cowen
Subscribe for More Information
August 12, 2014
15:53 EDTJAZZCanaccord to hold a conference
34th Annual Growth Conference to be held in Boston on August 13-14.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use